Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 965 for:    eczema

To Evaluate the in Use Tolerance of E45 Eczema Repair Emollient in Babies and Children With (Very(Dry/Atopic Skin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02857062
Recruitment Status : Completed
First Posted : August 5, 2016
Last Update Posted : February 8, 2017
Sponsor:
Collaborator:
Intertek
Information provided by (Responsible Party):
Reckitt Benckiser Healthcare (UK) Limited

Brief Summary:
The investigation will evaluate, under dermatological control, the cutaneous in-use tolerance of E45 Eczema Repair Emollient with two or three times daily application, over a period of two weeks on children and babies with dry/atopic and very dry/atopic skin.

Condition or disease Intervention/treatment Phase
Atopic Dermatitis / Eczema Device: E45 Eczema Repair Emollient Not Applicable

Detailed Description:

The investigation is an open label, in-use cutaneous tolerance investigation in children and babies with dry/atopic and very dry/atopic skin, to evaluate the acceptability and skin tolerability of E45 Eczema Repair Emollient.

The investigation will be an 'at home' user investigation where the test product will be applied by the parent/legal guardian to a pre-defined test site (arm or leg) between 2 to 3 times daily, consecutively for 14 days.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 34 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Open label, in use tolerance study in babies and children.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, In-use Tolerance Study in Babies and Children With Dry/Atopic and Very Dry/Atopic Skin, to Evaluate the Acceptability and Skin Tolerability of E45 Eczema Repair Emollient for the Treatment of Atopic or Eczema Prone Skin
Actual Study Start Date : November 23, 2016
Actual Primary Completion Date : February 2, 2017
Actual Study Completion Date : February 2, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eczema

Arm Intervention/treatment
Experimental: E45 Eczema Repair Emollient
Open label, single arm study to evaluate the skin tolerance of E45 Eczema Repair Emollient in babies and children
Device: E45 Eczema Repair Emollient
E45 Eczema Repair Emollient




Primary Outcome Measures :
  1. Cutaneous Tolerance [ Time Frame: 14 Days ]
    The total irritancy score (Erythema score + Oedema score + Papules score + Vesicles score) for each subject from baseline to end of study as observed by the investigation Dermatologist.

  2. Parental Assessment of Cutaneous Tolerance [ Time Frame: 14 Days ]
    The dermatologist will ask the parent/legal guardian to provide their assessment of tolerance by asking the parent/legal guardian if they considered the product to be well tolerated by their child/baby's skin

  3. Global Assessment of Cutaneous Tolerance [ Time Frame: 14 Days ]
    The dermatologist will make a 'global assessment' of tolerance for each subject based on reported product use/compliance



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   3 Months to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. be female or male
  2. be a child aged from ≥3 years to < 12 years or a baby aged from ≥3 months to < 36 months at screening
  3. be phototype I - IV (Fitzpatrick Phototyping Scale)
  4. have skin that is dry/atopic or very dry/atopic (confirmed by the Dermatologist in consultation with the parent/legal guardian)
  5. have mild atopic eczema (as confirmed by the Dermatologist in consultation with the parent/legal guardian) but not undergoing steroid treatment for the condition
  6. have only few or no pigmentation on the selected test site
  7. be in general good health and mental condition

    In addition the parent/legal guardian must:

  8. Both parents in case of shared custody/legal guardian will provide written informed consent for their child/baby to participate in the investigation (children aged 6 years and above, capable of understanding the investigation after it has been explained to them, will be asked to provide assent. Pre-schoolers (2-5 years) will be allowed to express a level of assent verbally relating to their ability to do so)
  9. agree to attend the investigation centre, with the child/baby, on the predefined days
  10. be willing and capable to follow the investigation requirements

Exclusion Criteria:

  1. have chronic or acute skin diseases, except atopic eczema on any part of the body
  2. have an active flare up of atopic eczema on any sites of the body at screening
  3. known allergy or sensitivity to cosmetic products and/or any ingredients of the investigational product.
  4. any systemic illness that would impact on the subjects safety or wellbeing and/or affect the response of the skin or the interpretation of the test results at screening (Day -14 to -7)
  5. receiving the following topical or systemic treatments at baseline (Day 0);

    • anti-inflammatory and/or anti-histamines during the previous week
    • cough suppressants and/or topical or inhaled corticosteroids during the previous 2 weeks
    • retinoids and/or immunosuppressants during the previous 6 months
  6. have diabetes, acute cardiac and circulatory diseases, HIV, hepatitis
  7. participation in other studies/investigations on any part of the body during the last 4 weeks
  8. use of dermatological therapeutics on the body within 7 days prior to baseline (Day 0) (use of such products on the face, trunk, hands and nappy area is permitted)
  9. swimming within 48 hours prior to baseline (Day 0)
  10. intensive/prolonged exposure to the sun within 30 days prior to screening
  11. planned changes to subject's diet during the investigation (e.g. weaning)
  12. subjects whose parent/legal guardian are employees or who work for a manufacturer of personal care products or for the testing facility
  13. subjects in protective care
  14. subjects whose parent/legal guardian (who will be applying the investigation product) is allergic to the investigation device ingredients
  15. Any clinically significant and relevant abnormalities of medical history and/or any condition or medication that would impact on the subject safety or well-being and/or affect the response of the skin or the interpretation of the test results in the opinion of the Principal Investigator or designee

Layout table for additonal information
Responsible Party: Reckitt Benckiser Healthcare (UK) Limited
ClinicalTrials.gov Identifier: NCT02857062     History of Changes
Other Study ID Numbers: 09224-02
First Posted: August 5, 2016    Key Record Dates
Last Update Posted: February 8, 2017
Last Verified: January 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Eczema
Dermatitis
Dermatitis, Atopic
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Emollients
Dermatologic Agents